Plus Therapeutics Inc
PSTV0.416USD
-0.015-3.60%
終値 09/19, 16:00（ET）15分遅れの株価
38.31M時価総額
損失額直近12ヶ月PER
詳細情報 Plus Therapeutics Inc 企業名
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
企業情報
企業コードPSTV
会社名Plus Therapeutics Inc
上場日Aug 09, 2000
最高経営責任者「CEO」Dr. Marc H. Hedrick, M.D.
従業員数21
証券種類Ordinary Share
決算期末Aug 09
本社所在地4200 Marathon Blvd.
都市AUSTIN
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号78756
電話番号17372557194
ウェブサイトhttp://www.plustherapeutics.com/
企業コードPSTV
上場日Aug 09, 2000
最高経営責任者「CEO」Dr. Marc H. Hedrick, M.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Robert P. Lenk, Ph.D.
Dr. Robert P. Lenk, Ph.D.
Independent Director
Independent Director
139.33K
+375.08%
Mr. Howard Clowes, J.D.
Mr. Howard Clowes, J.D.
Independent Director
Independent Director
26.50K
--
Dr. Marc H. Hedrick, M.D.
Dr. Marc H. Hedrick, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.43K
--
Mr. Kyle Guse, Esq.
Mr. Kyle Guse, Esq.
Independent Director
Independent Director
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew Sims, CPA
Mr. Andrew Sims, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Michael Stanley Rosol, Ph.D.
Dr. Michael Stanley Rosol, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Robert P. Lenk, Ph.D.
Dr. Robert P. Lenk, Ph.D.
Independent Director
Independent Director
139.33K
+375.08%
Mr. Howard Clowes, J.D.
Mr. Howard Clowes, J.D.
Independent Director
Independent Director
26.50K
--
Dr. Marc H. Hedrick, M.D.
Dr. Marc H. Hedrick, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.43K
--
Mr. Kyle Guse, Esq.
Mr. Kyle Guse, Esq.
Independent Director
Independent Director
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew Sims, CPA
Mr. Andrew Sims, CPA
Chief Financial Officer
Chief Financial Officer
--
--
収益内訳
通貨: USD更新時刻: Tue, Mar 4
通貨: USD更新時刻: Tue, Mar 4
FY2018
事業別USD
会社名
収益
比率
Consumable
2.17M
81.21%
Other products
277.00K
10.37%
Device
225.00K
8.42%
地域別USD
会社名
収益
比率
Japan
2.06M
77.05%
Americas
293.00K
10.97%
EMEA
270.00K
10.11%
Asia Pacific
50.00K
1.87%
事業別
地域別
事業別USD
会社名
収益
比率
Consumable
2.17M
81.21%
Other products
277.00K
10.37%
Device
225.00K
8.42%
株主
更新時刻: Fri, Aug 29
更新時刻: Fri, Aug 29
株主統計
種類
株主統計
株主統計
比率
S.H.N. Financial Investments Ltd
1.51%
Great Point Capital LLC
0.89%
Lenk (Robert P)
0.14%
Jane Street Capital, L.L.C.
0.12%
UBS Financial Services, Inc.
0.09%
他の
97.25%
株主統計
株主統計
比率
S.H.N. Financial Investments Ltd
1.51%
Great Point Capital LLC
0.89%
Lenk (Robert P)
0.14%
Jane Street Capital, L.L.C.
0.12%
UBS Financial Services, Inc.
0.09%
他の
97.25%
種類
株主統計
比率
Corporation
1.51%
Investment Advisor
1.03%
Individual Investor
0.26%
Research Firm
0.15%
Investment Advisor/Hedge Fund
0.05%
Hedge Fund
0.04%
他の
96.96%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
35
2.30M
3.80%
-2.38M
2025Q1
40
2.31M
11.85%
+1.40M
2024Q4
42
829.50K
14.07%
-98.90K
2024Q3
44
822.91K
13.96%
-122.82K
2024Q2
46
793.04K
13.90%
-131.21K
2024Q1
46
164.14K
3.77%
-119.25K
2023Q4
47
203.09K
4.50%
+1.47K
2023Q3
47
127.65K
2.90%
-110.39K
2023Q2
45
114.35K
4.03%
-124.09K
2023Q1
46
144.27K
6.00%
-86.09K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
S.H.N. Financial Investments Ltd
885.45K
1.74%
--
--
Apr 18, 2025
Great Point Capital LLC
885.45K
1.74%
--
--
Apr 18, 2025
Lenk (Robert P)
29.33K
0.06%
--
--
Apr 18, 2025
UBS Financial Services, Inc.
33.44K
0.07%
+33.44K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
57.05K
0.11%
-1.10K
-1.89%
Mar 31, 2025
Petersen (Gregory B)
48.92K
0.1%
--
--
Mar 04, 2025
The Vanguard Group, Inc.
32.54K
0.06%
--
--
Mar 31, 2025
Clowes (Howard)
26.50K
0.05%
--
--
Apr 18, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
日付
種類
比率
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
